{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T17:29:06Z","timestamp":1787678946066,"version":"build-2784847793"},"reference-count":40,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["521-2011-4339"],"award-info":[{"award-number":["521-2011-4339"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.xphs.2017.03.009","type":"journal-article","created":{"date-parts":[[2017,3,18]],"date-time":"2017-03-18T12:15:42Z","timestamp":1489839342000},"page":"2606-2613","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["The Impact of Liposomal Formulations on the Release and Brain Delivery of Methotrexate: An In\u00a0Vivo Microdialysis Study"],"prefix":"10.1016","volume":"106","author":[{"given":"Yang","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaap","family":"Rip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter J.","family":"Gaillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth C.M.","family":"de Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margareta","family":"Hammarlund-Udenaes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xphs.2017.03.009_bib1","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jddst.2015.07.007","article-title":"The \u201cfate\u201d of polymeric and lipid nanoparticles for brain delivery and targeting: strategies and mechanism of blood\u2013brain barrier crossing and trafficking into the central nervous system","volume":"32","author":"Tosi","year":"2016","journal-title":"J\u00a0Drug Deliv Sci Technol"},{"issue":"23-24","key":"10.1016\/j.xphs.2017.03.009_bib2","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.drudis.2008.09.005","article-title":"The targeted delivery of cancer drugs across the blood-brain barrier: chemical modifications of drugs or drug-nanoparticles?","volume":"13","author":"Juillerat-Jeanneret","year":"2008","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.xphs.2017.03.009_bib3","doi-asserted-by":"crossref","first-page":"238428","DOI":"10.1155\/2013\/238428","article-title":"Nanoparticles for brain drug delivery","volume":"2013","author":"Masserini","year":"2013","journal-title":"ISRN Biochem"},{"issue":"1","key":"10.1016\/j.xphs.2017.03.009_bib4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/1061186X.2016.1184272","article-title":"Nano carriers for drug transport across the blood-brain barrier","volume":"25","author":"Li","year":"2017","journal-title":"J\u00a0Drug Target"},{"issue":"8","key":"10.1016\/j.xphs.2017.03.009_bib5","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1080\/10611860903112842","article-title":"Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles","volume":"17","author":"Kurakhmaeva","year":"2009","journal-title":"J\u00a0Drug Target"},{"issue":"1-2","key":"10.1016\/j.xphs.2017.03.009_bib6","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jneuroim.2014.06.025","article-title":"Glutathione PEGylated liposomal methylprednisolone (2B3-201) attenuates CNS inflammation and degeneration in murine myelin oligodendrocyte glycoprotein induced experimental autoimmune encephalomyelitis","volume":"274","author":"Lee","year":"2014","journal-title":"J\u00a0Neuroimmunol"},{"issue":"2","key":"10.1016\/j.xphs.2017.03.009_bib7","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ejpb.2008.08.021","article-title":"Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB)","volume":"71","author":"Ulbrich","year":"2009","journal-title":"Eur J Pharm Biopharm"},{"issue":"5","key":"10.1016\/j.xphs.2017.03.009_bib8","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1021\/mp300272a","article-title":"Enhanced brain delivery of the opioid peptide DAMGO in glutathione pegylated liposomes: a microdialysis study","volume":"10","author":"Lindqvist","year":"2013","journal-title":"Mol Pharm"},{"issue":"1","key":"10.1016\/j.xphs.2017.03.009_bib9","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s11095-015-1774-3","article-title":"In\u00a0vivo functional evaluation of increased brain delivery of the opioid peptide DAMGO by glutathione-pegylated liposomes","volume":"33","author":"Lindqvist","year":"2016","journal-title":"Pharm Res"},{"key":"10.1016\/j.xphs.2017.03.009_bib10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jconrel.2016.02.026","article-title":"Nanocarriers for the treatment of glioblastoma multiforme: current state-of-the-art","volume":"227","author":"Karim","year":"2016","journal-title":"J\u00a0Control Release"},{"issue":"2","key":"10.1016\/j.xphs.2017.03.009_bib11","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.tibtech.2016.07.006","article-title":"Breaking down the barriers to precision cancer nanomedicine","volume":"35","author":"von Roemeling","year":"2017","journal-title":"Trends Biotechnol"},{"issue":"1","key":"10.1016\/j.xphs.2017.03.009_bib12","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3390\/pharmaceutics6010137","article-title":"Application of pharmacokinetic and pharmacodynamic analysis to the development of liposomal formulations for oncology","volume":"6","author":"Ait-Oudhia","year":"2014","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.xphs.2017.03.009_bib13","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jconrel.2015.02.012","article-title":"Enhanced glutathione PEGylated liposomal brain delivery of an anti-amyloid single domain antibody fragment in a mouse model for Alzheimer's disease","volume":"203","author":"Rotman","year":"2015","journal-title":"J\u00a0Control Release"},{"key":"10.1016\/j.xphs.2017.03.009_bib14","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ejps.2016.07.003","article-title":"Pharmacokinetic considerations of nanodelivery to the brain: using modeling and simulations to predict the outcome of liposomal formulations","volume":"92","author":"Lindqvist","year":"2016","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.xphs.2017.03.009_bib15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ddtec.2016.07.006","article-title":"Intracerebral microdialysis in blood-brain barrier drug research with focus on nanodelivery","volume":"20","author":"Hammarlund-Udenaes","year":"2016","journal-title":"Drug Discov Today Technol"},{"key":"10.1016\/j.xphs.2017.03.009_bib16","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ddtec.2016.07.005","article-title":"Liposome technologies and drug delivery to the CNS","volume":"20","author":"Rip","year":"2016","journal-title":"Drug Discov Today Technol"},{"issue":"5","key":"10.1016\/j.xphs.2017.03.009_bib17","doi-asserted-by":"crossref","first-page":"460","DOI":"10.3109\/1061186X.2014.888070","article-title":"Glutathione PEGylated liposomes: pharmacokinetics and delivery of cargo across the blood-brain barrier in rats","volume":"22","author":"Rip","year":"2014","journal-title":"J\u00a0Drug Target"},{"issue":"1","key":"10.1016\/j.xphs.2017.03.009_bib18","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s11060-008-9678-2","article-title":"Effect of blood\u00a0brain barrier permeability in recurrent high grade gliomas on the intratumoral pharmacokinetics of methotrexate: a microdialysis study","volume":"91","author":"Blakeley","year":"2009","journal-title":"J\u00a0Neurooncol"},{"issue":"8","key":"10.1016\/j.xphs.2017.03.009_bib19","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1023\/A:1018945529611","article-title":"Pharmacokinetics of methotrexate in the extracellular fluid of brain C6-glioma after intravenous infusion in rats","volume":"16","author":"Dukic","year":"1999","journal-title":"Pharm Res"},{"key":"10.1016\/j.xphs.2017.03.009_bib20","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejps.2013.12.020","article-title":"Prediction of methotrexate CNS distribution in different species\u2014influence of disease conditions","volume":"57","author":"Westerhout","year":"2014","journal-title":"Eur J Pharm Sci"},{"issue":"20","key":"10.1016\/j.xphs.2017.03.009_bib21","doi-asserted-by":"crossref","first-page":"6233","DOI":"10.1021\/jm901036q","article-title":"Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids","volume":"52","author":"Friden","year":"2009","journal-title":"J\u00a0Med Chem"},{"issue":"5","key":"10.1016\/j.xphs.2017.03.009_bib22","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/j.jpba.2006.12.034","article-title":"Determination of methotrexate and its major metabolite 7-hydroxymethotrexate in mouse plasma and brain tissue by liquid chromatography-tandem mass spectrometry","volume":"43","author":"Guo","year":"2007","journal-title":"J\u00a0Pharm Biomed Anal"},{"issue":"2","key":"10.1016\/j.xphs.2017.03.009_bib23","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1124\/dmd.105.007211","article-title":"Brain distribution of cetirizine enantiomers: comparison of three different tissue-to-plasma partition coefficients: K(p), K(p,u), and K(p,uu)","volume":"34","author":"Gupta","year":"2006","journal-title":"Drug Metab Dispos"},{"issue":"8","key":"10.1016\/j.xphs.2017.03.009_bib24","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1007\/s11095-007-9502-2","article-title":"On the rate and extent of drug delivery to the brain","volume":"25","author":"Hammarlund-Udenaes","year":"2008","journal-title":"Pharm Res"},{"issue":"3","key":"10.1016\/j.xphs.2017.03.009_bib25","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/annonc\/mdh097","article-title":"Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer","volume":"15","author":"O'Brien","year":"2004","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.xphs.2017.03.009_bib26","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/CAD.0000000000000182","article-title":"Emerging delivery systems to reduce doxorubicin cardiotoxicity and improve therapeutic index: focus on liposomes","volume":"26","author":"Tahover","year":"2015","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.xphs.2017.03.009_bib27","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jconrel.2015.05.286","article-title":"Tumor vascular targeted liposomal-bortezomib minimizes side effects and increases therapeutic activity in human neuroblastoma","volume":"211","author":"Zuccari","year":"2015","journal-title":"J\u00a0Control Release"},{"key":"10.1016\/j.xphs.2017.03.009_bib28","series-title":"Drug Delivery to the Brain-Physiological Concepts, Methodologies and Approaches","article-title":"Blood-to-brain drug delivery using nanocarriers","author":"Gaillard","year":"2014"},{"issue":"4","key":"10.1016\/j.xphs.2017.03.009_bib29","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1080\/107175401317245912","article-title":"Prolonged blood circulation of methotrexate by modulation of liposomal composition","volume":"8","author":"Hong","year":"2001","journal-title":"Drug Deliv"},{"issue":"24","key":"10.1016\/j.xphs.2017.03.009_bib30","doi-asserted-by":"crossref","first-page":"6074","DOI":"10.1021\/acs.langmuir.6b00741","article-title":"Atomic force microscopic analysis of the effect of lipid composition on liposome membrane rigidity","volume":"32","author":"Takechi-Haraya","year":"2016","journal-title":"Langmuir"},{"issue":"1","key":"10.1016\/j.xphs.2017.03.009_bib31","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jcis.2004.05.042","article-title":"Mechanical properties and stability measurement of cholesterol-containing liposome on mica by atomic force microscopy","volume":"278","author":"Liang","year":"2004","journal-title":"J\u00a0Colloid Interface Sci"},{"issue":"1-2","key":"10.1016\/j.xphs.2017.03.009_bib32","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.bbamem.2004.03.006","article-title":"Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer","volume":"1663","author":"Charrois","year":"2004","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"10.1016\/j.xphs.2017.03.009_bib33","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1124\/dmd.112.049254","article-title":"Brain efflux index to investigate the influence of active efflux on brain distribution of pemetrexed and methotrexate","volume":"41","author":"Li","year":"2013","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"10.1016\/j.xphs.2017.03.009_bib34","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1124\/dmd.113.055228","article-title":"The effect of ABCG2 and ABCC4 on the pharmacokinetics of methotrexate in the brain","volume":"42","author":"Sane","year":"2014","journal-title":"Drug Metab Dispos"},{"issue":"51","key":"10.1016\/j.xphs.2017.03.009_bib35","doi-asserted-by":"crossref","first-page":"30429","DOI":"10.1074\/jbc.M115.692103","article-title":"ATP-binding cassette subfamily C member 5 (ABCC5) functions as an efflux\u00a0transporter of glutamate conjugates and analogs","volume":"290","author":"Jansen","year":"2015","journal-title":"J\u00a0Biol Chem"},{"issue":"4","key":"10.1016\/j.xphs.2017.03.009_bib36","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s11095-006-9780-0","article-title":"Pharmacokinetic consequences of active drug efflux at the blood-brain barrier","volume":"23","author":"Syvanen","year":"2006","journal-title":"Pharm Res"},{"issue":"18","key":"10.1016\/j.xphs.2017.03.009_bib37","doi-asserted-by":"crossref","first-page":"6596","DOI":"10.1073\/pnas.0707046105","article-title":"Release of hydrophobic molecules from polymer micelles into cell membranes revealed by Forster resonance energy transfer imaging","volume":"105","author":"Chen","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Pt A","key":"10.1016\/j.xphs.2017.03.009_bib38","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jconrel.2015.10.013","article-title":"A\u00a0critical evaluation of drug delivery from ligand modified nanoparticles: confounding small molecule distribution and efficacy in the central nervous system","volume":"220","author":"Cook","year":"2015","journal-title":"J\u00a0Control Release"},{"issue":"1","key":"10.1016\/j.xphs.2017.03.009_bib39","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1021\/mp800137z","article-title":"Intracellular drug delivery by poly(lactic-co-glycolic acid) nanoparticles, revisited","volume":"6","author":"Xu","year":"2009","journal-title":"Mol Pharm"},{"issue":"11","key":"10.1016\/j.xphs.2017.03.009_bib40","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1172\/JCI106181","article-title":"Treatment of leukemia with large doses of methotrexate and folinic acid: clinical-biochemical correlates","volume":"48","author":"Hryniuk","year":"1969","journal-title":"J\u00a0Clin Invest"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354917301661?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354917301661?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,3]],"date-time":"2018-09-03T07:53:00Z","timestamp":1535961180000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354917301661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S0022354917301661"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2017.03.009","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Impact of Liposomal Formulations on the Release and Brain Delivery of Methotrexate: An In\u00a0Vivo Microdialysis Study","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2017.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}